Evaluation of the efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1-infected patients

Antiviral Therapy

Volumn 1, Issue 1, 1996, Pages 42-50

  Staszewski, Schlomo ^a,i   Miller, Veronica ^a   Kober, Astrid ^a   Colebunders, Robert ^b   Vandercam, Bernard ^c   Delescluse, Jacques ^d   Clumeck, Nathan ^e   Van Wanzeele, Filip ^f   De Brabander, Marc ^g   De Creé, Jean ^g   Moeremans, Marc ^g   Andries, Koen ^g   Boucher, Charles ^h   Stoffels, Paul ^g   Janssen, Paul A J ^g  

^a GOETHE UNIVERSITY   (Germany)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d University Clinic of Brussels   (Belgium)

^e SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

^g JANSSEN RESEARCH FOUNDATION   (Belgium)

^h ACADEMIC MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAMIDE DERIVATIVE; ACETOPHENONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL MARKER; INTERLEUKIN 2 RECEPTOR; LOVIRIDE; NEOPTERIN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; BLOOD; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; ISOLATION AND PURIFICATION; LYMPHOCYTE SUBPOPULATION; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT REFUSAL;

ACETAMIDES; ACETOPHENONES; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; LYMPHOCYTE SUBSETS; MALE; NEOPTERIN; RECEPTORS, INTERLEUKIN-2; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT REFUSAL;

EID: 0029677210     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Boom R, Sol CJA, Salimans MMM, Janssen CL, Werthem-Van Dillen PME & Van Der Noordaa J. Rapid and simple method for purification of nucleic acids. Journal of Clinical Microbiology 1990; 28:495-503.
2. Castro KG, Ward WJ, Slutsker L, Buehler JW, Jaffe HW, Berkelman RL & Curran JW. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Clinical Infectious Diseases 1993; 17:802-810.
3. 3. IX International Conference on AIDS, Berlin, Germany, 6-11 June 1993; Abs. PO-B26-1999.
4. De Bethune MP, Pauwels R, Andries K, Vandamme AM, Peeters M, Colebunders R, Stoffels P, De Clercq E & Desmyter J. AZT resistance reversal by the non-nucleoside reverse transcriptase inhibitor α-APA R018893 in a symptomatic HIV-infected individual. II International Workshop on HIV Drug Resistance, Noordwijk, The Netherlands 1993.
5. De Cree J, De Brabander M, Geukens H, Vandenbruaene M, Woestenborghs R, Van de Velde V, Van Den Broeck R, Stoffels P, Camvenbergh G, Colebunders R, Verhaegen H & Janssen PAJ. Clinical pharmacology of loviride (R 089439), a potent α-APA RT-inhibitor on HIV-1 negative and positive volunteers. Acta Antwerpiensia 1994; 11:21-28.
6. De Cree J, De Brabander M, Vandenbruaene M, Colebunders R, Stoffels P, Woestenborghs R, Van de Velde V, Cauwenbergh G, Verhaegen H & Janssen PAJ. Clinical pharmacology of R018893 in 7 asymptomatic HIV-1 positive subjects. Acta Amtwerpiensia 1993; 10:20-24.
7. Dueweke TJ, Kezdy FJ, Waszak GA, Deibel MR & Tarpley WG. The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type reverse transcriptase. Journal of Biological Chemistry 1992; 267:27-30.
8. Goldman ME, Nunberg JH, O'Brien JA, Quintero JC, Schleif JC, Hoffman JM, Anderson PS, Hupe DJ, Emini EA & Stern AM. Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proceedings of the National Academy of Sciences, USA 1991; 88:6863-6867.
9. Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA, Greenough TC, Sullivan JL, Hall D, Myers M, Lamson M & Richman DD. High dose nevirapine: Safety, pharmacokinetics and antiviral effect in patients with human immunodeficiency virus. Journal of Infectious Diseases 1995; 171:537-545.
10. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM & Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature, London 1995; 373: 123-126.
11. Kaye S, Loveday C & Tedder RS. A microtitre format point mutation assay: Application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine. Journal of Medical Virology 1992; 37:241-246.
12. Larder BA. 3′Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrobial Agents & Chemotherapy 1992; 36:2664-2669.
13. Malone J, Simms T, Gray G, Wagner K, Burge J & Burke D. Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important. Journal of Acquired Immune Deficiency Syndromes 1990; 3:144-151.
14. Merluzzi VJ, Hargrave DK, Labadia M, Grozinger K, Skoog M, Wu JC, Shih CK, Eckner K, Hattox S, Adams J, Rosenthal AS, Faanes R, Eckner RJ, Koup RA & Sullivan JL. Inhibition of HIV-1 replication by a non-nucleoside reverse transcriptase inhibitor. Science 1990; 250:1411-1413.
15. Mientjes GH, Van Ameijden EJ, Roos MT, De Leeuw NA, Van Den Hoeck JA, Coutintro RA & Miedema FF. Large diurnal variation in CD4 cell count and T-cell function among drug users: implications for clinical practice and epidemiological studies. AIDS 1992; 6:1269-1272.
16. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L & Kwok S. Rapid and simple PCR assay for quantitation of HIV-1 RNA in plasma. Application to acute retroviral infection. Journal of Clinical Microbiology 1994; 32:292-300.
17. Pauwels R, Andries K, Debyser Z, Van Daele P, Schols D, Stoffels P, De Vreese K, Woestenborghs R, Vandamme AM, Janssen CGM, Anne J, Cauwenbergh G, Desmyter J, Heykants J, Janssen MAC, De Clercq E & Janssen PAJ. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proceedings of the National Academy of Sciences, USA 1993; 90:1711-1715.
18. Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, Raeymaeckers A, Van Gelder J, Woestenborghs R, Heykants J, Schellekens K, Janssen MAC, De Clercq E & Janssen PAJ. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature, London 1990; 343: 470-474.
19. Pialoux G, Youle M, Dupont B, Gazzard B, Cauwenbergh G, Stoffels P, Davies S, De Saint Martin J & Janssen PAJ. Pharmacokinetics of R 82913 in patients with AIDS or AIDS-related complex. Lancet 1991; 338:140-143.
20. Richman DD. Loss of nevirapine activity associated with the emergence of resistance in clinical trials. VIII International Conference on AIDS, Amsterdam, The Netherlands, 19-24 July 1992; PoB 3576.
21. Richman DD, Shih CK, Lowy I, Rose J, Prodanovich G & Griffin J. Human immunodeficiency virus typ mutants resistant to non-nucleoside inhibitors of reverse transcriptase arise in tissue culture. Proceedings of the National Academy of Sciences, USA 1991; 88:11241-11245.
22. Saag MS, Emini AE, Laskin OL, Douglas J, Lapidus WI, Schleif WA, Whitley RJ, Hildebrand C, Byrnes VW, Kappes JC, Anderson KW, Massari FE, Shaw GM & the L-697,661 Working Group. A short term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. New England Journal of Medicine 1993; 329:1065-1072.
23. Spence RA, Kati WM, Anderson KS & Johnson KA. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995; 267:988-991.
24. Staszewski S, Massari FE, Kober A, Gohler R, Durr S, Anderson KW, Schneider CL, Waterbury JA, Bakshi KK, Taylor VI, Hildebrand CS, Kreisl C, Hoffstedt B, Schleif WA, von Briesen H, Rubsamen-Waigmann H, Calandra GB, Ryan JL, Stille W, Emini EA & Byrnes VW. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high level resistance to L-697,661, a non-nucleoside reverse transcriptase inhibitor. Journal of Infections Diseases 1995; 171:159-165.